Literature DB >> 12466031

Generalized anxiety disorder: comorbidity, comparative biology and treatment.

David J Nutt1, James C Ballenger, David Sheehan, Hans-Ulrich Wittchen.   

Abstract

Generalized anxiety disorder (GAD) is a severe and chronic anxiety disorder characterized by uncontrollable worrying and somatic anxiety (tension, insomnia and hypervigilance). It is a common condition, with lifetime prevalence rates for DSM-IV GAD in the general population of approx. 5-6% being reported. In addition, like other anxiety disorders, GAD also shows comorbidity with depression and most of the other anxiety disorders. This article reviews data on the prevalence of GAD, its comorbidity with depression, and its social and economic impact. Proposed neurobiological mechanisms for GAD are discussed, since an understanding of these may help in the development of future therapies. Finally, current pharmacological and non-pharmacological treatment options for GAD are reviewed, with particular attention being paid to published clinical-trial data.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12466031     DOI: 10.1017/S1461145702003048

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  27 in total

1.  Prefrontal cortical contributions during discriminative fear conditioning, extinction, and spontaneous recovery in rats.

Authors:  Erin L Zelinski; Nancy S Hong; Amanda V Tyndall; Brett Halsall; Robert J McDonald
Journal:  Exp Brain Res       Date:  2010-05-07       Impact factor: 1.972

Review 2.  Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.

Authors:  Simone Tambaro; Marco Bortolato
Journal:  Recent Pat CNS Drug Discov       Date:  2012-04-01

Review 3.  Finding gene-environment interactions for generalised anxiety disorder.

Authors:  Alice M Gregory; Jennifer Y F Lau; Thalia C Eley
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-03       Impact factor: 5.270

Review 4.  [Patients with epilepsy and anxiety disorders. Diagnosis and treatment].

Authors:  S Beyenburg; D Schmidt
Journal:  Nervenarzt       Date:  2005-09       Impact factor: 1.214

Review 5.  Orexin, stress, and anxiety/panic states.

Authors:  Philip L Johnson; Andrei Molosh; Stephanie D Fitz; William A Truitt; Anantha Shekhar
Journal:  Prog Brain Res       Date:  2012       Impact factor: 2.453

Review 6.  Up-regulation of neurosteroid biosynthesis as a pharmacological strategy to improve behavioural deficits in a putative mouse model of post-traumatic stress disorder.

Authors:  Graziano Pinna; Ann M Rasmusson
Journal:  J Neuroendocrinol       Date:  2012-01       Impact factor: 3.627

7.  Profile of adverse events with duloxetine treatment: a pooled analysis of placebo-controlled studies.

Authors:  Stephen Brunton; Fujun Wang; S Beth Edwards; Antonio S Crucitti; Melissa J Ossanna; Daniel J Walker; Michael J Robinson
Journal:  Drug Saf       Date:  2010-05-01       Impact factor: 5.606

8.  Colonization with the commensal fungus Candida albicans perturbs the gut-brain axis through dysregulation of endocannabinoid signaling.

Authors:  Laura Markey; Andrew Hooper; Laverne C Melon; Samantha Baglot; Matthew N Hill; Jamie Maguire; Carol A Kumamoto
Journal:  Psychoneuroendocrinology       Date:  2020-07-24       Impact factor: 4.905

Review 9.  MicroRNA's impact on neurotransmitter and neuropeptide systems: small but mighty mediators of anxiety.

Authors:  Stefanie Martinetz
Journal:  Pflugers Arch       Date:  2016-04-30       Impact factor: 3.657

10.  Group II metabotropic glutamate receptor type 2 allosteric potentiators prevent sodium lactate-induced panic-like response in panic-vulnerable rats.

Authors:  Philip L Johnson; Stephanie D Fitz; Eric A Engleman; Kjell A Svensson; Jeffrey M Schkeryantz; Anantha Shekhar
Journal:  J Psychopharmacol       Date:  2012-08-21       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.